다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Annals of hepatology : official journal of the Mexican Association of Hepatology, v.1 no.1, 2002년, pp.12 - 19
Angulo, Paul
AI-Helper
Treatment of patients with nonalcoholic fatty liver disease (NAFLD) has typically been focused on the management of associated conditions such as obesity, diabetes mellitus and hyperlipidemia. NAFLD associated with obesity may resolve with weight reduction, although the benefits of weight loss have ...
Mayo Clin Proc Ludwig 55 342 1980 Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease
Prog Liver Dis Schaffner 8 283 1986 Nonalcoholic fatty liver disease
N Engl J Med Angulo 2002 10.1056/NEJMra011775 Nonalcoholic fatty liver disease
Hum Pathol Lee 20 594 1989 10.1016/0046-8177(89)90249-9 Nonalcoholic steatohepatitis. A study of 49 patients
Hepatology Powell 11 74 1990 10.1002/hep.1840110114 The natural history of nonalcoholic steatohepatitis: A follow up study of forty-two patients for up to 21 years
Gastroenterology Bacon 107 1103 1994 10.1016/0016-5085(94)90235-6 Nonalcoholic steatohepatitis: an expanded clinical entity
Hepatology Teli 22 1714 1995 10.1002/hep.1840220616 The natural history of nonalcoholic fatty liver: A follow up study
Gastroenterology Matteoni 116 1413 1999 10.1016/S0016-5085(99)70506-8 Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity
Gastroenterology Ratziu 118 1117 2000 10.1016/S0016-5085(00)70364-7 Liver fibrosis in overweight patients
Hepatology Angulo 30 1356 1999 10.1002/hep.510300604 Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Gastroenterology Diehl 95 1056 1989 10.1016/0016-5085(88)90183-7 Alcohol-like liver disease in nonalcoholic. A clinical and histological comparison with alcohol-induced liver injury
A Med Scand Eriksson 220 83 1986 10.1111/j.0954-6820.1986.tb02733.x Nonalcoholic steatohepatitis in obesity: a reversible condition
A J DigDis Rozental 12 198 1967 Liver morphology and function tests in obesity and during total starvation
N Engl J Med Drenick 282 829 1970 10.1056/NEJM197004092821502 Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass
Gastroenterology Palmer 99 1408 1990 10.1016/0016-5085(90)91169-7 Effect of weight reduction on hepatic abnormalities in overweight patients
Hepatology Andersen 12 224 1991 10.1016/0168-8278(91)90942-5 Hepatic effects of dietary weight loss in morbidly obese patients
Hepatology Ueno 27 103 1997 10.1016/S0168-8278(97)80287-5 Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
J Pediatr Vajro 125 239 1994 10.1016/S0022-3476(94)70202-0 Persistent hyperaminotransferasemia resolving after weight reduction in obese children
Dig Dis Sci Franzese 42 1428 1997 10.1023/A:1018850223495 Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population
J Pediatr Gastroenterol and Nutr Rashid 30 48 2000 10.1097/00005176-200001000-00017 Nonalcoholic steatohepatitis in children
Kanders 197 1994 Obesity:Pathophysiology, Psychology and Treatment. Very-low-calorie diets for the treatment of obesity
Drug Safety Kolanowski 20 119 1999 10.2165/00002018-199920020-00003 A risk-benefit assessment of anti-obesity drugs
N Engl J Med Abenhaim 335 609 1996 10.1056/NEJM199608293350901 Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Nat Med Lin 6 998 2000 10.1038/79697 Metformin reverses fatty liver disease in obese, leptin-deficient mice
JAMA DeWind 236 2298 1976 10.1001/jama.1976.03270210024017 Intestinal bypass surgery for morbid obesity. Long term results
Arch Inter Med Campbell 137 602 1977 10.1001/archinte.1977.03630170034012 Jejunoileal bypass as a treatment of morbid obesity
Surg Gynecol and Obst Ackerman 149 8 1979 Protein supplementation in the management of degenerating liver function after jejunoileal bypass
Gastroenterology Drenick 82 535 1982 10.1016/S0016-5085(82)80403-4 Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazol, irrespective of protein-calorie malnutrition
Gastroenterology Buchman 102 1363 1992 10.1016/0016-5085(92)90777-V Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition in rats
Hepatology Buchman 22 1390 1995 Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation
J Surg Res Pappo 51 106 1991 10.1016/0022-4804(91)90078-Z Polymixin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in rat
J Surg Res Freud 38 356 1985 10.1016/0022-4804(85)90049-6 A possible beneficial effect of metronidazol in reducing TPN-associated liver function derangements
Hepatology Laurin 23 1464 1996 10.1002/hep.510230624 Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: A pilot study
J Hepatol Basaranoglu 31 384 1999 10.1016/S0168-8278(99)80243-8 A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
Hepatology Guma 26 387A 1997 Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: Results of a prospective clinical controlled trial [Abstract]
Hepatology Ceriani 28 386A 1998 Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis [Abstract]
J Hepatology Holoman 32 210 2000 10.1016/S0168-8278(00)81130-7 Serum markers of liver fibrosis in patients with non-alcoholic steatohepatitis (NASH). Correlation to liver morphology and effect of therapy
Alcohol Clin Exp Res Barak 17 552 1993 10.1111/j.1530-0277.1993.tb00798.x Dietary betaine promotes generation of hepatitic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration
Am J Gastroenterol Abdelmalek 96 2711 2001 10.1111/j.1572-0241.2001.04129.x Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study
Gastroenterology Gulbahar 118 A1444 2000 10.1016/S0016-5085(00)81671-6 Treatment of non-alcoholic steatohepatitis with N-acetylcysteine [Abstract]
Hepatology Hasegawa 26 250A 1997 Long-and short-term d-alpha-tocopherol supplementation inhibits liver collagen alpha-1(I) gene expression [Abstract]
J Pediatr Lavine 136 734 2000 10.1016/S0022-3476(00)05040-X Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
Aliment Pharmacol and Ther Hasegawa 15 1667 2001 10.1046/j.1365-2036.2001.01083.x Plasma trnasforming growth factor-β1 level and efficacy of a-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study
Gastroenterology Angulo 120 1281 2001 10.1053/gast.2001.23591 Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue
Diabet Med Day 16 179 1999 10.1046/j.1464-5491.1999.00023.x Thiazolidinediones: a new class of antidiabetic drugs
Am J Gastroenterol Caldwell 96 519 2001 10.1111/j.1572-0241.2001.03553.x A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
N Engl J Med Watkins 338 908 1998 10.1056/NEJM199803263381314 Hepatic dysfunction associated with troglitazone
Lancet Marchesini 358 893 2001 10.1016/S0140-6736(01)06042-1 Metformin in non-alcoholic steatohepatitis
J Hepatol Letterson 24 200 1996 10.1016/S0168-8278(96)80030-4 Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice
Hepatology Jaeschke 24 238A. 1996 Reactive oxygen species activate the transcription factor NF-KB in the liver by induction of lipid peroxidation [Abstract]
Atherosclerosis Acosta 20 417 1974 10.1016/0021-9150(74)90023-9 Injury produce by free fatty acids to lysosomes and mitochondria in cultures heart muscle and endothelial cells
Gastroenterology Weltman 111 1645 1996 10.1016/S0016-5085(96)70028-8 Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation
J Clin Investi Leclercq 105 1067 2000 10.1172/JCI8814 CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis
Hepatology Weltman 27 128 1998 10.1002/hep.510270121 Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
Hepatology Schuppan 30 1099 1999 10.1002/hep.510300437 Herbal products for liver diseases. A therapeutic challenge for the new millennium
PNAS Yang 94 2557 1997 10.1073/pnas.94.6.2557 Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis
J Biol Chem Chavin 274 5692 1999 10.1074/jbc.274.9.5692 Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion
JAMA Cortez-Pinto 282 1659 1999 10.1001/jama.282.17.1659 Alterations in liver ATP homeostasis in human nonalcoholic steatoheaptitis. A pilot study
Gastroenterology George 114 311 1998 10.1016/S0016-5085(98)70482-2 Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
J Hepatol Boncovsky 31 421 1999 10.1016/S0168-8278(99)80032-4 Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
Hepatology Younossi 30 847 1999 10.1002/hep.510300407 Hepatic iron and nonalcoholic fatty liver disease
Gastroenterology Desai 118 A975 2000 10.1016/S0016-5085(00)86044-8 Phlebotomy reduces transaminase levels in patients with nonalcoholic steatohepatitis [Abstract]
Gastroenterology Nitecki 118 A1474 2000 10.1016/S0016-5085(00)81800-4 Effect of phlebotomy on nonalcoholic steatohepatitis (NASH) [Abstract]
Liver Transpl Charlton 7 608 2001 10.1053/jlts.2001.25453 Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease
Liver Transpl Contos 7 363 2001 10.1053/jlts.2001.23011 Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.